# A Study to Collect Survival Data on Patients Previously Enrolled in Abraxane Pancreatic Cancer Study CA046.

> **NCT02021500** · — · COMPLETED · sponsor: **Celgene** · enrollment: 40 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** ABI-007

## Key facts

- **NCT ID:** NCT02021500
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01-02
- **Primary completion:** 2015-04-16
- **Final completion:** 2015-04-16
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2019-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02021500

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02021500, "A Study to Collect Survival Data on Patients Previously Enrolled in Abraxane Pancreatic Cancer Study CA046.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02021500. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*